Table 2. Association of JMJD2A, LSD1 and AR levels with patient clinicopathologic traits, disease recurrence and cancer-specific mortality in tumor specimens.

Fishers exact p-values are shown for each statistical association. Dark shading = significant (p<0.05). Superficial (Ta, T1, CIS) and muscle invasive (T2, T3, T4) bladder cancers. NMI:non muscle invasive; MI= muscle invasive ; BC: bladder confined, EVE; extravsical.

Marker	JMJD2A		LSD1		AR
	% Positivity	Intensity	% Positivity	Intensity	% Positivity	Intensity
	p value		p value		p value
CLINICAL
Age	0.101	0.817	0.560	0.294	0.638	0.821
Gender	0.557	0.06	0.200	0.582	0.961	0.900
Race	0.121	0.911	0.565	0.821	0.686	0.926
Smoking: Any History	0.344	1	0.533	0.669	0.705	1
Active	0.027	0.001	0.562	0.755	0.606	0.317
Body Mass Index	0.535	0.114	0.273	0.595	0.998	0.37
Prior Pelvic Radiation	0.241	0.787	0.831	1	1	0.428
Hydronephrosis	0.736	0.065	0.856	0.573	0.619	0.537
Intravesical Chemotherapy	0.813	0.298	0.969	0.289	0.009	0.189
Neoadjuvant Chemotherapy	0.664	0.465	0.09	0.141	0.637	0.666
HISTOPATHOLOGIC
Malignant vs. Benign	<0.001	0.012	0.493	0.096	<0.001	<0.001
Stage:
Overall	<0.001	<0.001	0.639	0.121	0.014	0.443
Superficial vs Invasive	<0.001	<0.001	0.574	0.006	0.358	0.35
NMI vs MU	0.001	<0.001	1	0.012	0.028	0.382
BC vs EVE	0.177	0.001	0.939	0.046	0.092	0.376
Lymphovascular Invasion	0.062	0.016	1	0.129	0.762	0.532
Perineural Invasion	0.417	0.097	0.777	0.165	0.496	0.496
Presence of CIS	0.033	1	0.649	0.485	0.894	0.191
Positive Bladder Margin	0.687	0.125	0.426	0.565	1	0.619
Lymph Node: Positivity	0.034	0.141	0.225	0.084	0.02	0.166
Density	0.088	0.309	0.204	0.112	0.256	0.082
Stage	0.022	0.028	0.306	0.155	0.675	0.276
SURVIVAL
Disease-free survival	0.799	0.409	0.372	0.494	0.284	0.409
Cancer Specific Survival	0.896	0.761	0.885	0.810	0.665	0.456
Overall Survival	0.064	0.033	0.740	0.402	0.766	0.745